Market Overview

Stocks That Battle Cancer Were The Best-Performing Biotechs In January

Stocks That Battle Cancer Were The Best-Performing Biotechs In January
Related NVS
The Current State Of The Breast Cancer Treatment Space
A Smart Idea Among Europe ETFs
Related CELG
Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst
Benzinga's Top Upgrades, Downgrades For May 5, 2017

Motif Investing is a new way for investors to own a collection of stocks in a certain "motif."

Through the website, an investor can easily identify which trends might be profitable and buy an allotment of pre-selected stocks in that trend, for a low price ($9.99).

The site also allows for the selected stocks and weightings in each motif to be changed by the investor.

The top returner (within the biotech space) for the month of January is the "Battling Cancer" motif.

Through January, the motif is up 8 percent, while the S&P 500 ETF is down 1.73 percent.

The motif owns a collection of 25 stocks that are battling cancer in four different sectors: Medical Devices, Mature Biotech, Pharmaceutical and Early Stage Biotech.

The highest-weighted stocks in the portfolio are:

1. Novartis AG (ADR) (NYSE: NVS) at 25 percent

2. Celgene Corporation (NASDAQ: CELG) at 24.1 percent

3. Pharmacyclics, Inc. (NASDAQ: PCYC) at 10.6 percent

4. Exact Sciences Corporation (NASDAQ: EXAS) at 4.5 percent

5. Tesaro (NASDAQ: TSRO) at 4.1 percent

The best performers in the portfolio for January are:

1. Foundation Medicine Inc (NASDAQ: FMI) at 109.1 percent

2. Pharmacyclics, Inc. (NASDAQ: PCYC) at 34.9 percent

3. Bind Therapeutics Inc (NASDAQ: BIND) at 29.7 percent

4. Kite Pharma Inc (NASDAQ: KITE) at 28.2 percent

5. Celldex Therapeutics, Inc. (NASDAQ: CLDX) at 22.5 percent

Image credit: Sergey Golyshev, Flickr

Posted-In: Long Ideas Trading Ideas Best of Benzinga


Related Articles (CELG + BIND)

View Comments and Join the Discussion!